Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence

Neurobiology of Aging

Volumn 22, Issue 6, 2001, Pages 811-817

  Zandi, Peter P ^a   Breitner, J C S ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PLACEBO; ROFECOXIB; SULINDAC;

ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; HUMANS;

EID: 0035696257     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(01)00297-4     Document Type: Article

References (79)

1. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
2. Inflammation and Alzheimer' disease
3. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer' disease? The Rotterdam Study
4. Reduced prevalence of AD in users of NSAIDs and H2 receptorNantagonists: The Cache County study
5. Cortical distribution of neurofibrillary tangles in Alzheimer' disease matches the pattern of neurons that retain their capacity of plastic remodelling in the adult brain
6. Rheumatoid arthritis and susceptibility to Alzheimer' disease
7. Nonsteroidal anti-inflammatory drug use and Alzheimer' disease: A case-control study in Rochester, Minnesota, 1980 through 1984
8. Inverse association of anti-inflammatory treatments and Alzheimer' disease: Initial results of co-twin control study
9. Delayed onset of Alzheimer' disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
10. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
11. Medical history and the risk of Alzheimer' disease: A collaborative re- analysis of case-control studies
12. Anti-inflammatory drugs protect against Alzheimer disease at low doses
13. A case-control study of Alzheimer' disease in Australia
14. Projections of Alzheimer' disease in the United States and the public health impact of delaying disease onset
15. The amyloid precursor protein of Alzheimer' disease is released by human platelets
16. The Canadian Study of Health and Aging: Risk factors for Alzheimer' disease in Canada
17. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins
18. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
19. Platelets are the primary source of amyloid beta-peptide in human blood
20. Sources of variability in prevalence rates of Alzheimer' disease
21. Inflammation and Alzheimer' disease: Relationships between pathogenic mechanisms and clinical expression
22. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase
23. A case-control study of dementia of the Alzheimer type
24. Microglia and the immune pathology of Alzheimer disease
25. A case-control study of Alzheimer' disease
26. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
27. The failures of success
28. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis
29. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample
30. Aspirin, anti-inflammatory drugs, and risk of dementia
31. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture
32. Alzheimer' disease: A study of epidemiological aspects
33. Cyclooxygenase expression in microglia and neurons in Alzheimer' disease and control brain
34. Analgesics - Antipyretic, and anti-inflammatory agents, and drugs employed in the treatment of gout
35. NSAIDs and incident Alzheimer' disease. The Rotterdam Study
36. Rheumatoid arthritis and senile dementia of the Alzheimer' type
37. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia
38. Education and the prevalence of dementia and Alzheimer' disease
39. Increased expression of cyclooxygenases and peroxisome proliferator-Nactivated receptor-gamma in Alzheimer' disease brains
40. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
41. The increasing prevalence of mental disorders: A pandemic threat
42. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
43. Ionotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways
44. A case-control study of Alzheimer' disease in China
45. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer' disease
46. Nonsteroidal antiinflammatory drug use in Alzheimer' disease
47. Pyramidal nerve cell loss in Alzheimer' disease
48. Calcium and free radicals: Mediators of neurotrophic factor and excitatory transmitter-regulated developmental plasticity and cell death
49. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture
50. Mechanisms of cell death in Alzheimer disease - Immunopathology
51. Anti-inflammatory drugs, and Alzheimer disease
52. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer' disease: A review of 17 epidemiologic studies
53. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype
54. Alzheimer' disease, and rheumatoid arthritis
55. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology
56. Localization and distribution of cyclooxygenase-2 in brain tissue by immunohistochemistry
57. A serum-, and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
58. cDNA cloning, and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase
59. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies
60. Cyclooxygenase and inflammation in Alzheimer' disease: Experimental Napproaches and clinical interventions
61. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer' disease brain
62. Apolipoprotein E, and cognitive decline in Alzheimer' disease
63. Molecular mechanisms associated with long-term consolidation of the NMDA signals
64. Preclinical evidence of Alzheimer' disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
65. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer' disease
66. Nonsteroidal anti-inflammatory drugs in Alzheimer' disease
67. Clinical trial of indomethacin in Alzheimer' disease
68. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer' disease
69. Dendritic spine formation and pruning: Common cellular mechanisms?
70. Toward a comprehensive theory for Alzheimer' disease. Hypothesis: Alzheimer' disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein
71. Alzheimer' disease. A radical vascular connection
72. Risk of Alzheimer' disease and duration of NSAID use
73. Cerebrovascular endothelial dysfunction mediated by beta-amyloid
74. Beta-Amyloid-mediated vasoactivity, and vascular endothelial damage
75. Cyclooxygenases 1, and 2
76. Inflammation and the mechanism of action of anti-inflammatory drugs
77. Effect of hydrochloroquine on progression of dementia in early Alzheimer' disease: An 18-month randomized, placebo controlled study
78. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs